About Melinta Therapeutics (NASDAQ:MLNT)
Melinta Therapeutics, Inc. develops and commercializes novel antibiotics designed to provide therapeutic solutions. The Company’s lead product is Baxdela, an antibiotic approved by the United States food and drug administration (FDA) for use in the treatment of acute bacterial skin and skin structure infections (ABSSSI). The Company also has an extensive pipeline of preclinical and clinical stage products This pipeline includes many important classes of antibiotics, each targeted at a different segment of the anti-infective market.
Industry, Sector and Symbol
Industry Bio Therapeutic Drugs
Trailing P/E Ratio-1.77111716621253
Forward P/E Ratio-2.59
Sales & Book Value
Annual Sales$18.02 million
Price / Sales22.60
Price / CashN/A
Book Value$17.50 per share
Price / Book0.74
Return on Equity-45.72%
Return on Assets-35.83%
Melinta Therapeutics (NASDAQ:MLNT) Frequently Asked Questions
What is Melinta Therapeutics' stock symbol?
Melinta Therapeutics trades on the NASDAQ under the ticker symbol "MLNT."
How were Melinta Therapeutics' earnings last quarter?
Melinta Therapeutics, Inc. (NASDAQ:MLNT) released its quarterly earnings results on Thursday, October, 27th. The biotechnology company reported ($0.62) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.64) by $0.02. The biotechnology company earned $4 million during the quarter, compared to the consensus estimate of $3.90 million. Melinta Therapeutics had a negative return on equity of 45.72% and a negative net margin of 500.05%. The business's revenue was up 60.0% on a year-over-year basis. During the same quarter in the previous year, the company posted ($0.63) EPS. View Melinta Therapeutics' Earnings History.
Where is Melinta Therapeutics' stock going? Where will Melinta Therapeutics' stock price be in 2018?
6 Wall Street analysts have issued 1-year target prices for Melinta Therapeutics' stock. Their forecasts range from $2.00 to $4.00. On average, they expect Melinta Therapeutics' stock price to reach $3.25 in the next twelve months. View Analyst Ratings for Melinta Therapeutics.
What are Wall Street analysts saying about Melinta Therapeutics stock?
Here are some recent quotes from research analysts about Melinta Therapeutics stock:
- 1. According to Zacks Investment Research, "Melinta Therapeutics, Inc. develops and commercializes novel antibiotics designed to provide new and better therapeutic solutions. Melinta's lead product is Baxdela, an antibiotic approved by the US FDA for use in the treatment of acute bacterial skin and skin structure infections (ABSSSI). Melinta also has an extensive pipeline of preclinical and clinical stage products that were developed internally or assumed under the 2017 acquisition of Cempra, Inc. This pipeline includes many important classes of antibiotics, each targeted at a different segment of the anti-infective market. Melinta is headquartered in New Haven, CT. " (2/8/2018)
- 2. Robert W. Baird analysts commented, "Cempra announced this morning that the MAA filed in Europe has been withdrawn. We believe it is likely due to the same safety concerns brought up by the FDA. At this point, the path forward for solithromycin appears to us to be a dead end and any additional expenditures will only diminish the company's otherwise attractive cash position. We reiterate our Underperform rating." (3/28/2017)
- 3. Stifel Nicolaus analysts commented, "Incremental solithromycin updates provided on management's 4Q16 earnings announcement/call now meaningfully increase the likelihood this asset ' in its current formulation ' is unlikely to represent a source of any future value. In addition to FDA seemingly reiterating its stance on wanting 9,000 patients of additional CABP data to assuage hepatotoxicity concerns, EMA is now requesting additional data and management's commentary would suggest any regulatory path forward here is likely to prove challenging. Solithromycin also failed to achieve non-inferiority within the primary cohort of the P3 SOLITAIRE-U trial (gonorrhea), the NASH study has been suspended, and the COPD study has been closed. We've removed all solithromycin-related value (ex-Japan) from our model and believe any viable commercialization argument for Taksta is likely to hinge on YE17 P2 prosthetic joint infection data. Target decreased to $4 (previously $8)." (3/1/2017)
Are investors shorting Melinta Therapeutics?
Melinta Therapeutics saw a increase in short interest in January. As of January 31st, there was short interest totalling 972,778 shares, an increase of 68.2% from the January 12th total of 578,332 shares. Based on an average trading volume of 177,247 shares, the short-interest ratio is currently 5.5 days. Currently, 6.1% of the shares of the stock are sold short.
Who are some of Melinta Therapeutics' key competitors?
Some companies that are related to Melinta Therapeutics include Adaptimmune Therapeutics (ADAP), Vanda Pharmaceuticals (VNDA), Jounce Therapeutics (JNCE), Raptor Pharmaceutical (RPTP), Uniqure (QURE), La Jolla Pharmaceutical (LJPC), Sorrento Therapeutics (SRNE), Rhythm Pharmaceuticals (RYTM), Karyopharm Therapeutics (KPTI), Reata Pharmaceuticals (RETA), Kura Oncology (KURA), Rocket Pharmaceuticals (RCKT), Inflarx (IFRX), Akebia Therapeutics (AKBA), Urogen Pharma (URGN), NuCana (NCNA), Five Prime Therapeutics (FPRX) and Aclaris Therapeutics (ACRS).
Who are Melinta Therapeutics' key executives?
Melinta Therapeutics' management team includes the folowing people:
- Kevin T. Ferro, Chairman of the Board (Age 45)
- Daniel M. Wechsler, President, Chief Executive Officer, Director (Age 46)
- Paul Estrem, Chief Financial Officer
- Lisa DeFrancesco, Senior Vice President - Investor Relations
- Lyn Baranowski, Senior Vice President - Corporate Development and Strategy
- Peter DiRoma, Senior Vice President - Regulatory Affairs and Quality Assurance
- Erin M. Duffy Ph.D., Chief Scientific Officer (Age 45)
- Suzie Paulson, Vice President of Human Resources
- Kevin Conway, Vice President - Program Management and Technical Operations
- Sue Cammarata M.D., Chief Medical Officer
Who owns Melinta Therapeutics stock?
Melinta Therapeutics' stock is owned by a number of of retail and institutional investors. Top institutional shareholders include Vatera Holdings LLC (21.48%), BlackRock Inc. (1.93%), Millennium Management LLC (0.89%), Sphera Funds Management LTD. (0.64%), Deutsche Bank AG (0.30%) and Renaissance Technologies LLC (0.26%). Company insiders that own Melinta Therapeutics stock include David Moore, David N Gill, Dov A Md Goldstein and Vatera Healthcare Partners Llc. View Institutional Ownership Trends for Melinta Therapeutics.
Who bought Melinta Therapeutics stock? Who is buying Melinta Therapeutics stock?
Melinta Therapeutics' stock was bought by a variety of institutional investors in the last quarter, including Vatera Holdings LLC, BlackRock Inc., Millennium Management LLC, Sphera Funds Management LTD., Deutsche Bank AG, Renaissance Technologies LLC, Geode Capital Management LLC and TIAA CREF Investment Management LLC. Company insiders that have bought Melinta Therapeutics stock in the last two years include David Moore, David N Gill and Vatera Healthcare Partners Llc. View Insider Buying and Selling for Melinta Therapeutics.
How do I buy Melinta Therapeutics stock?
Shares of Melinta Therapeutics can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Melinta Therapeutics' stock price today?
One share of Melinta Therapeutics stock can currently be purchased for approximately $13.00.
How big of a company is Melinta Therapeutics?
Melinta Therapeutics has a market capitalization of $407.23 million and generates $18.02 million in revenue each year. The biotechnology company earns $-117,960,000.00 in net income (profit) each year or ($7.34) on an earnings per share basis. Melinta Therapeutics employs 45 workers across the globe.
How can I contact Melinta Therapeutics?
Melinta Therapeutics' mailing address is 300 George St Ste 301, NEW HAVEN, CT 06511-6663, United States. The biotechnology company can be reached via phone at +1-312-7670291 or via email at [email protected]
MarketBeat Community Rating for Melinta Therapeutics (MLNT)MarketBeat's community ratings are surveys of what our community members think about Melinta Therapeutics and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.
Melinta Therapeutics (NASDAQ:MLNT) Analysts' Consensus Rating (How are Consensus Ratings Calculated?)
MarketBeat calculates consensus analyst ratings for company stocks using the most recent rating from each brokerage that has rated a stock within the last twelve months. Since brokers often use different ratings systems, each rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months.
MarketBeat will no longer include ratings and price target data in its consensus calculation if a broker drops coverage and MarketBeat has received a report that coverage was dropped. Ratings from certain research firms that issue ratings using purely quantitative methods (such as Zacks, Vetr and ValuEngine) are not included in consensus calculations. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
|Today||30 Days Ago||90 Days Ago||180 Days Ago|
|Consensus Rating: ||Hold||Hold||Hold||Hold|
|Consensus Rating Score: ||2.17||2.17||1.92||1.93|
|Ratings Breakdown: ||0 Sell Rating(s)|
5 Hold Rating(s)
1 Buy Rating(s)
0 Strong Buy Rating(s)
|0 Sell Rating(s)|
5 Hold Rating(s)
1 Buy Rating(s)
0 Strong Buy Rating(s)
|2 Sell Rating(s)|
10 Hold Rating(s)
1 Buy Rating(s)
0 Strong Buy Rating(s)
|3 Sell Rating(s)|
10 Hold Rating(s)
2 Buy Rating(s)
0 Strong Buy Rating(s)
|Consensus Price Target: ||$3.25||$3.25||$6.46||$12.40|
|Price Target Upside: ||79.37% downside||79.37% downside||180.92% upside||239.82% upside|
Melinta Therapeutics (NASDAQ:MLNT) Consensus Price Target History
Melinta Therapeutics (NASDAQ:MLNT) Analyst Ratings History
(Data available from 2/19/2016 forward)
Melinta Therapeutics (NASDAQ:MLNT) Earnings History and Estimates Chart
Melinta Therapeutics (NASDAQ MLNT) Earnings History by Quarter
(Earnings results data provided by Zacks Investment Research)
|Date||Quarter||Consensus Estimate||Actual EPS||Revenue Estimate||Actual Revenue||Release Link||Conference Call||Details|
|8/9/2017||Q2 2017||($0.32)||($0.23)||$3.58 million||$0.86 million||View||Listen|
|4/28/2017||Q1 2017||($0.53)||($0.37)||$3.55 million||$4.87 million||View||N/A|
|2/28/2017||Q4 2016||($0.57)||($0.60)||$4.19 million||$7.95 million||View||Listen|
|10/27/2016||Q3||($0.64)||($0.62)||$3.90 million||$4.00 million||View||Listen|
|8/1/2016||Q2||($0.67)||($0.51)||$3.89 million||$3.42 million||View||N/A|
|5/1/2016||Q1||($0.63)||($0.61)||$3.94 million||$2.70 million||View||N/A|
|2/24/2016||Q4||($0.59)||($0.48)||$3.89 million||$5.79 million||View||Listen|
|10/22/2015||Q315||($0.52)||($0.63)||$4.70 million||$2.50 million||View||Listen|
|7/29/2015||Q2||($0.41)||($0.57)||$4.60 million||$5.05 million||View||Listen|
|4/30/2015||Q1||($0.43)||($0.41)||$2.90 million||$13.96 million||View||Listen|
|2/25/2015||Q414||($0.46)||($0.46)||$3.50 million||$2.47 million||View||Listen|
|10/29/2014||Q314||($0.59)||($0.34)||$1.59 million||$7.77 million||View||N/A|
|7/29/2014||Q214||($0.56)||($0.49)||$2.56 million||$1.90 million||View||N/A|
|4/29/2014||Q114||($0.48)||($0.51)||$2.10 million||$3.10 million||View||N/A|
|2/27/2014||Q413||($0.42)||($0.51)||$1.25 million||$2.07 million||View||N/A|
|10/29/2013||Q313||($0.29)||($0.41)||$0.46 million||$1.20 million||View||N/A|
|7/30/2013||Q3 2013||($0.42)||($0.16)||$5.13 million||$4.60 million||View||N/A|
Melinta Therapeutics (NASDAQ:MLNT) Earnings Estimates
Current Year EPS Consensus Estimate: $-5.02 EPS
Next Year EPS Consensus Estimate: $-5.62 EPS
Dividend History for Melinta Therapeutics (NASDAQ:MLNT)
No dividend announcements for this company have been tracked by MarketBeat.com
Melinta Therapeutics (NASDAQ MLNT) Insider Trading and Institutional Ownership History
Insider Ownership Percentage: 31.50%
Melinta Therapeutics (NASDAQ MLNT) Insider Trades by Quarter
(Data available from 1/1/2013 forward)
|Transaction Date||Insider Name||Title||Buy/Sell||Number of Shares||Average Share Price||Total Transaction||Shares Held After Transaction||Details|
|1/5/2018||Vatera Healthcare Partners Llc||Director||Buy||5,777,778||$13.50||$78,000,003.00|| |
|3/8/2017||Dov A Md Goldstein||Director||Sell||150,000||$3.55||$532,500.00||95|| |
|1/13/2017||Dov A Md Goldstein||Director||Sell||105,460||$3.40||$358,564.00||95|| |
|1/6/2017||Dov A Md Goldstein||Director||Sell||937,600||$3.41||$3,197,216.00||95|| |
|1/3/2017||David N Gill||Director||Buy||5,000||$2.94||$14,700.00||5,000|| |
|3/1/2016||David Moore||Insider||Buy||500||$16.18||$8,090.00||1,500|| |
|1/4/2016||Dov A. Md Goldstein||Director||Sell||842||$30.06||$25,310.52||50|| |
|12/15/2015||David W. Oldach||insider||Sell||10,000||$30.27||$302,700.00||1,100|| |
|11/9/2015||David W. Oldach||insider||Sell||12,200||$28.78||$351,116.00||1,100|| |
|10/26/2015||Garheng Kong||Director||Buy||2,830||$17.43||$49,326.90||2,830|| |
|6/22/2015||Dov A Md Goldstein||Director||Sell||50,000||$35.74||$1,787,000.00|| |
|5/23/2014||John Johnson||Director||Buy||10,000||$9.10||$91,000.00|| |
|6/19/2013||P Sherrill Neff||Director||Buy||265,000||$7.00||$1,855,000.00|| |
Melinta Therapeutics (NASDAQ MLNT) News Headlines
|Melinta Therapeutics, Inc. (MLNT) Receives Consensus Rating of "Hold" from Analysts|
www.americanbankingnews.com - February 13 at 1:38 AM
|$3.28 Million in Sales Expected for Melinta Therapeutics, Inc. (MLNT) This Quarter|
www.americanbankingnews.com - February 12 at 2:26 AM
|Melinta Therapeutics, Inc. (MLNT) Short Interest Up 68.2% in January|
www.americanbankingnews.com - February 11 at 1:32 AM
|Melinta Therapeutics (MLNT) Downgraded by Zacks Investment Research|
www.americanbankingnews.com - February 8 at 12:56 PM
|Melinta Therapeutics (MLNT) Lowered to Strong Sell at BidaskClub|
www.americanbankingnews.com - February 3 at 7:40 PM
|Wired News – Melinta Launched Intravenous and Oral Formulations of Baxdela(TM) in the US|
finance.yahoo.com - January 31 at 10:09 AM
|Melinta Therapeutics Launches Antibiotic Baxdela™ (delafloxacin) in the United States|
finance.yahoo.com - January 29 at 9:57 AM
| Analysts Expect Melinta Therapeutics, Inc. (MLNT) to Post -$0.59 Earnings Per Share|
www.americanbankingnews.com - January 24 at 9:24 PM
|Melinta Therapeutics, Inc. (MLNT) Receives Consensus Recommendation of "Hold" from Analysts|
www.americanbankingnews.com - January 19 at 1:32 AM
|Vatera Healthcare Partners Llc Acquires 5,777,778 Shares of Melinta Therapeutics, Inc. (MLNT) Stock|
www.americanbankingnews.com - January 9 at 9:38 PM
|Zacks: Analysts Expect Melinta Therapeutics, Inc. (MLNT) Will Announce Quarterly Sales of $3.28 Million|
www.americanbankingnews.com - January 9 at 3:36 AM
|Melinta Therapeutics Completes Acquisition of The Medicines Company's Infectious Disease Portfolio - GlobeNewswire (press release)|
globenewswire.com - January 8 at 8:59 AM
| Brokerages Anticipate Melinta Therapeutics, Inc. (MLNT) to Announce -$0.59 EPS|
www.americanbankingnews.com - January 7 at 5:26 PM
|4 Biotech Stocks to Watch in the New Year - Nasdaq|
www.nasdaq.com - January 5 at 6:01 PM
|Melinta Therapeutics to Present at 36th Annual JP Morgan Healthcare Conference - GlobeNewswire (press release)|
globenewswire.com - January 3 at 11:20 AM
|Melinta Therapeutics to Present at 36th Annual J.P. Morgan Healthcare Conference|
finance.yahoo.com - January 3 at 11:20 AM
|Melinta Therapeutics Appoints Lisa DeFrancesco as Senior Vice President of Investor Relations - GlobeNewswire (press release)|
globenewswire.com - January 2 at 8:16 PM
|Melinta Therapeutics, Inc. (MLNT) Sees Significant Increase in Short Interest|
www.americanbankingnews.com - December 31 at 4:22 AM
|Melinta: Acquisition As Growth Strategy - Seeking Alpha|
seekingalpha.com - December 29 at 8:22 AM
|ETFs with exposure to Melinta Therapeutics, Inc. : December 26, 2017|
finance.yahoo.com - December 28 at 5:31 PM
|Melinta Therapeutics, Inc. (MLNT) Given Average Recommendation of "Hold" by Brokerages|
www.americanbankingnews.com - December 25 at 1:57 AM
|Zacks: Brokerages Anticipate Melinta Therapeutics, Inc. (MLNT) Will Announce Earnings of -$0.59 Per Share|
www.americanbankingnews.com - December 22 at 10:08 AM
|ETFs with exposure to Melinta Therapeutics, Inc. : December 15, 2017|
finance.yahoo.com - December 15 at 7:02 PM
| Brokerages Expect Cempra, Inc. (MLNT) Will Post Quarterly Sales of $2.48 Million|
www.americanbankingnews.com - December 6 at 5:54 AM
|ETFs with exposure to Melinta Therapeutics, Inc. : December 5, 2017|
finance.yahoo.com - December 5 at 6:16 PM
|Zacks: Brokerages Anticipate Cempra, Inc. (MLNT) to Announce -$0.74 Earnings Per Share|
www.americanbankingnews.com - December 4 at 1:26 PM
|Gabelli Weighs in on Cempra, Inc.'s FY2017 Earnings (MLNT)|
www.americanbankingnews.com - December 4 at 1:52 AM
|Cempra (MLNT) Cut to Strong Sell at ValuEngine|
www.americanbankingnews.com - December 3 at 7:30 AM
|Cempra (MLNT) Stock Rating Upgraded by Gabelli|
www.americanbankingnews.com - November 30 at 11:22 AM
|Cempra (MLNT) Lifted to "Buy" at Ladenburg Thalmann Financial Services|
www.americanbankingnews.com - November 30 at 7:34 AM
|Cempra, Inc. (MLNT) Given Average Rating of "Hold" by Analysts|
www.americanbankingnews.com - November 30 at 4:08 AM
|Melinta Therapeutics, Inc. – Value Analysis (NASDAQ:MLNT) : November 28, 2017|
finance.yahoo.com - November 28 at 6:20 PM
|Melinta Therapeutics, Inc. breached its 50 day moving average in a Bullish Manner : MLNT-US : November 27, 2017|
finance.yahoo.com - November 27 at 4:55 PM
|Why Earnings Season Could Be Great for Cempra (MLNT) - Nasdaq|
www.nasdaq.com - November 23 at 6:31 AM
|Cempra, Inc. (MLNT) Stock Rating Upgraded by Zacks Investment Research|
www.americanbankingnews.com - November 18 at 10:52 PM
| Analysts Anticipate Cempra, Inc. (MLNT) Will Announce Quarterly Sales of $2.48 Million|
www.americanbankingnews.com - November 18 at 11:58 AM
| Brokerages Anticipate Cempra, Inc. (MLNT) Will Announce Earnings of -$0.82 Per Share|
www.americanbankingnews.com - November 16 at 3:10 AM
|Melinta Therapeutics Reports First Patient Treated in Phase 2 Study of Topical Radezolid for Treatment of Acne|
finance.yahoo.com - November 13 at 5:59 PM
|Head-To-Head Comparison: Cempra (MLNT) and Its Peers|
www.americanbankingnews.com - November 9 at 5:30 PM
www.americanbankingnews.com - November 9 at 1:12 AM
www.americanbankingnews.com - November 8 at 5:45 PM
Melinta Therapeutics (NASDAQ:MLNT) SEC Filings
This page is loading this company's SEC Filings. Please wait...
Melinta Therapeutics (NASDAQ:MLNT) Income Statement, Balance Sheet and Cash Flow Statement
Melinta Therapeutics (NASDAQ MLNT) Stock Chart for Monday, February, 19, 2018